We report a tunable chemical genetics approach for enhancing genetic code expansion in different wild-type bacterial strains that employ apidaecin-like, antimicrobial peptides observed to temporarily sequester and thereby inhibit Release Factor 1 (RF1). In a concentration-dependent matter, these peptides granted a conditional lambda phage resistance to a recoded strain with nonessential RF1 activity and promoted multisite nonstandard amino acid (nsAA) incorporation at in-frame amber stop codons and . When exogenously added, the peptides stimulated specific nsAA incorporation in a variety of sensitive, wild-type (RF1+) strains, including , a species in which nsAA incorporation has not been previously reported. Improvement in nsAA incorporation was typically 2-15-fold in BL21, MG1655, and DH10B strains and with the >20-fold improvement observed in probiotic Nissle 1917. In-cell expression of these peptides promoted multisite nsAA incorporation in transcripts with up to 6 amber codons, with a >35-fold increase in BL21 showing moderate toxicity. Leveraging this RF1 sensitivity allowed multiplexed partial recoding of MG1655 and DH10B that rapidly resulted in resistant strains that showed an additional approximately twofold boost to nsAA incorporation independent of the peptide. Finally, in-cell expression of an apidaecin-like peptide library allowed the discovery of new peptide variants with reduced toxicity that still improved multisite nsAA incorporation >25-fold. In parallel to genetic reprogramming efforts, these new approaches can facilitate genetic code expansion technologies in a variety of wild-type bacterial strains.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acschembio.0c00055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Applications of genetic code expansion in live cells are widespread and continually emerging, yet they have been limited by their reliance on the supplementation of non-standard amino acids (nsAAs) to cell culturing media. While advances in cell-free biocatalysis are improving nsAA synthesis cost and sustainability, such processes remain reliant on multi-step processes of product isolation followed by supplementation to engineered cells. Here, we report the design of a modular and genetically encoded system that combines the steps of biosynthesis of diverse phenylalanine derivatives, which are the most frequently used family of nsAAs for genetic code expansion, and their site-specific incorporation within target proteins using a single engineered bacterial host.
View Article and Find Full Text PDFSelective and Site-Specific Incorporation of Nonstandard Amino Acids Within Proteins for Therapeutic Applications.
Methods Mol Biol
October 2023
Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, USA.
The incorporation of nonstandard amino acids (nsAAs) within protein sequences has broadened the chemical functionalities available for use in the study, prevention, or treatment of disease. The ability to genetically encode the introduction of nsAAs at precise sites of target recombinant proteins has enabled numerous applications such as bioorthogonal conjugation, thrombin inhibition, intrinsic biological containment of live organisms, and immunochemical termination of self-tolerance. Genetic systems that perform critical steps in enabling nsAA incorporation are known as orthogonal translation systems or orthogonal aminoacyl-tRNA synthetase/tRNA pairs.
View Article and Find Full Text PDFExploring the relationship between North Star Ambulatory Assessment and Health Utilities Index scores in Duchenne muscular dystrophy.
Health Qual Life Outcomes
July 2023
Sarepta Therapeutics, Inc., Cambridge, MA, USA.
Background: The North Star Ambulatory Assessment (NSAA) documents motor performance in ambulatory individuals with Duchenne muscular dystrophy (DMD). Health Utilities Index (HUI) scores, reflecting preferences for health-related quality-of-life (HRQoL) implications of health states, are commonly estimated within trials. This study sought to characterize the relationship between the NSAA score and utility in DMD.
View Article and Find Full Text PDFGenotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials.
Neurology
April 2023
From the Dubowitz Neuromuscular Centre (F.M., M.C., A.Y.M.), NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London, and Great Ormond Street Hospital Trust, United Kingdom; Analysis Group, Inc. (J.S., G.S., H.L., M.J., I.D.), Boston; The Collaborative Trajectory Analysis Project (J.S., S.J.W.), Cambridge, MA; Department of Physical Medicine and Rehabilitation, and Pediatrics (C.M.), University of California, Davis, Sacramento; Child Neurology (N.G.), University Hospitals Leuven, Belgium; Department of Neurology (E.H.N.), Leiden University Medical Centre, the Netherlands; Department of Pediatrics (B.W.), University of Massachusetts Medical School, Worcester; MDUK Oxford Neuromuscular Center (L.S.), Department of Paediatrics, University of Oxford, United Kingdom and Neuromuscular Center of Liège (L.S.), Division of Paediatrics, CHU and University of Liège, Belgium; John Walton Muscular Dystrophy Research Centre (V.S., M.G.), Newcastle University and Newcastle Hospitals NHS Foundation Trust, United Kingdom; Department of Rehabilitation (I.J.M.d.G.), Donders Centre of Neuroscience, Radboud University Nijmegen Medical Center, the Netherlands; Cincinnati Children's Hospital Medical Center (C.T.), and College of Medicine (C.T.), University of Cincinnati, OH; Department of Pediatric Neurology (E.M.), Fondazione Policlinico Gemelli IRCCS, Catholic University, Rome, Italy; and Department of Human Genetics (A.A.-R.), Leiden University Medical Center, the Netherlands.
Article Synopsis
- Clinical trials for Duchenne muscular dystrophy (DMD) typically use genotype-matched controls, which complicates patient enrollment due to this rare disease's limited pool.
- The study analyzed over 1,600 patient-years from multiple sources to understand the impact of different genotype classes on motor function changes over a year.
- Results indicated that genotype only accounted for about 2% of variation in motor function outcomes, suggesting that utilizing unmatched controls in trials could be a viable option.
Incorporation of a Chemically Diverse Set of Non-Standard Amino Acids into a Gram-Positive Organism.
Bio Protoc
September 2022
Department of Chemical and Biological Engineering, University of Delaware, Newark, DE, USA.
The incorporation of non-standard amino acids (nsAAs) within proteins and peptides through genetic code expansion introduces novel chemical functionalities such as photo-crosslinking and bioconjugation. Given the utility of in fundamental and applied science, we extended existing nsAA incorporation technology from into , demonstrating incorporation of 20 unique nsAAs. The nsAAs we succeeded in incorporating within proteins conferred properties that included fluorescence, photo-crosslinking, and metal chelation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!